alanine has been researched along with Acute Respiratory Distress Syndrome in 13 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "BACKGROUNDSevere coronavirus disease 2019 (COVID-19) is associated with a dysregulated immune response, which can result in cytokine-release syndrome and acute respiratory distress syndrome (ARDS)." | 3.11 | Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. ( Anderson, C; Neil, GA; Perlin, DS; Raines, S; Ware, CF; Wilkins, HJ; Zafir-Lavie, I, 2022) |
| "He developed severe sepsis and acute respiratory distress syndrome (ARDS) and received intravenous high dose corticosteroid and tocilizumab to counter SARS-CoV2 associated cytokine surge." | 2.72 | Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature. ( Ahmed, M; Begum, SM; Islam, B; Islam, Z, 2021) |
| "The novel coronavirus disease 2019 (COVID-19) has led to a global pandemic since its emergence from Wuhan, China, in December of 2019." | 1.72 | Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD. ( Blanco, R; Haider, N; Patel, RH; Pella, PM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, RH | 1 |
| Pella, PM | 1 |
| Haider, N | 1 |
| Blanco, R | 1 |
| Perlin, DS | 1 |
| Neil, GA | 1 |
| Anderson, C | 1 |
| Zafir-Lavie, I | 1 |
| Raines, S | 1 |
| Ware, CF | 1 |
| Wilkins, HJ | 1 |
| Sanville, B | 1 |
| Corbett, R | 1 |
| Pidcock, W | 1 |
| Hardin, K | 1 |
| Sebat, C | 1 |
| Nguyen, MV | 1 |
| Thompson, GR | 1 |
| Haczku, A | 1 |
| Schivo, M | 1 |
| Cohen, S | 1 |
| Douedi, S | 1 |
| Miskoff, J | 1 |
| Berlin, DA | 1 |
| Gulick, RM | 1 |
| Martinez, FJ | 1 |
| Prajapati, S | 1 |
| Sharma, M | 1 |
| Kumar, A | 1 |
| Gupta, P | 1 |
| Narasimha Kumar, GV | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Bos, LDJ | 1 |
| Brodie, D | 1 |
| Calfee, CS | 1 |
| Maveddat, A | 1 |
| Mallah, H | 1 |
| Rao, S | 1 |
| Ali, K | 1 |
| Sherali, S | 1 |
| Nugent, K | 1 |
| Ledford, H | 1 |
| Matias, WR | 1 |
| Vaidya, A | 1 |
| Brigl, M | 1 |
| Bebell, LM | 1 |
| Copaescu, A | 1 |
| James, F | 1 |
| Mouhtouris, E | 1 |
| Vogrin, S | 1 |
| Smibert, OC | 1 |
| Gordon, CL | 1 |
| Drewett, G | 1 |
| Holmes, NE | 1 |
| Trubiano, JA | 1 |
| Islam, B | 1 |
| Ahmed, M | 1 |
| Islam, Z | 1 |
| Begum, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury[NCT04412057] | Phase 2 | 88 participants (Actual) | Interventional | 2020-07-17 | Completed | ||
| The Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.[NCT04407260] | 136 participants (Actual) | Observational | 2020-03-06 | Completed | |||
| Nation-wide Cross-sectional Survey on Current Pharmacological Practices in Severe COVID-19[NCT04691921] | 1,055 participants (Actual) | Observational | 2021-01-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Respiratory failure defined based on resource utilization requiring at least one of the following:~Endotracheal intubation and mechanical ventilation~Oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5)~Noninvasive positive pressure ventilation,~Extracorporeal membrane oxygenation" (NCT04412057)
Timeframe: Baseline to Day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| CERC-002 | 26 |
| Placebo | 20 |
1-month mortality defined as the number of subjects who are alive at the Day 28/ET visit (NCT04412057)
Timeframe: Baseline to Day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| CERC-002 | 36 |
| Placebo | 36 |
4 reviews available for alanine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
Severe Covid-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Brain; COVID-19; COVID | 2020 |
Severe Covid-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Brain; COVID-19; COVID | 2020 |
Severe Covid-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Brain; COVID-19; COVID | 2020 |
Severe Covid-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Brain; COVID-19; COVID | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature.
Topics: Adenosine Monophosphate; Adult; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antivira | 2021 |
1 trial available for alanine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Alanine; Antibodies, Monoclonal; COVID-19; | 2022 |
8 other studies available for alanine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Kidne | 2022 |
A Community-transmitted Case of Severe Acute Respiratory Distress Syndrome (SARS) Due to SARS-CoV-2 in the United States.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Community-Acquired Infections; COVID-19; | 2020 |
Novel coronavirus 2019 (COVID-19): A case report and review of treatments.
Topics: Adenosine Monophosphate; Aged; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical L | 2020 |
An update on novel COVID-19 pandemic: a battle between humans and virus.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Severe COVID-19 Infections-Knowledge Gained and Remaining Questions.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug | 2021 |
Why do COVID death rates seem to be falling?
Topics: Adenosine Monophosphate; Age Distribution; Age Factors; Aged; Aged, 80 and over; Alanine; Antibodies | 2020 |
A Patient with Fever and Dyspnea.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Combined Modality Ther | 2020 |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Bacteremi | 2021 |